Century Therapeutics, Inc. (IPSC) shareholders
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.63−0.11 (-6.32%)
Close on Nov 12, 2026Market cap $295.15MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
87.3%
158M of 181M shares
Institutional holders
99
37 new, 10 sold out
Net institutional buying
19M
In Q2 2026
Insider trades, 12 months
3 buys · 20 sales
Net bought $10.72K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 17,944,649 | 9.90% | 13G (passive) | Jan 9, 2026 |
| Chen Yu | 17,754,430 | 9.90% | 13G (passive) | Jan 9, 2026 |
| Deep Track Capital, LP Joint filing with David Kroin (7.34%), Deep Track Biotechnology Master Fund, Ltd. (5.78%) | 13,486,400 | 7.34% | 13G (passive) | Jan 8, 2026 |
| Commodore Capital Master LP Joint filing with Commodore Capital LP (7.10%), Robert Egen Atkinson (7.10%) and 1 more | 13,043,478 | 7.10% | 13G (passive) | Jan 9, 2026 |
| Nimish Shah Joint filing with Venrock Healthcare Capital Partners III, L.P. (7.10%), VHCP Co-Investment Holdings III, LLC (7.10%) and 4 more | 13,043,478 | 7.10% | 13G (passive) | Jan 9, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (7.10%) | 13,043,478 | 7.10% | 13G (passive) | Mar 31, 2026 |
| Versant Venture Capital VI, L.P. Joint filing with Versant Ventures VI GP, L.P. (19.10%), Versant Ventures VI GP-GP, LLC (19.10%) | 11,452,014 | 19.10% | 13G (passive) amendment | Dec 31, 2023 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (6.80%), Steven A. Cohen (6.80%) | 5,961,563 | 6.80% | 13G (passive) amendment | Dec 23, 2025 |
| Boxer Capital, LLC Joint filing with Boxer Asset Management Inc. (5.80%), Joe Lewis (5.80%) | 4,901,603 | 5.80% | 13G (passive) | Apr 15, 2024 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (5.40%), Steven A. Cohen (5.40%) | 4,725,639 | 5.40% | 13G (passive) | Dec 23, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IPSC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 17,754,430 | 9.80% | $43.50M | – | 0.38% |
| TCG Crossover Management, LLC | 17,754,430 | 9.80% | $43.40M | – | 1.04% |
| Versant Venture Management, LLC | 12,166,109 | 6.72% | $29.81M | – | 18.33% |
| Deep Track Capital, LP | 9,462,645 | 5.23% | $23.18M | −25,100 | 0.34% |
| Rtw Investments, LP | 8,695,652 | 4.80% | $21.30M | – | 0.18% |
| VR Adviser, LLC | 8,695,652 | 4.80% | $21.30M | – | 0.65% |
| Commodore Capital LP | 8,695,652 | 4.80% | $21.30M | – | 1.27% |
| BlackRock, Inc. | 8,091,768 | 4.47% | $19.82M | +6,567,346 | 0.00% |
| Vanguard Capital Management LLC | 5,703,680 | 3.15% | $13.97M | +17,476 | 0.00% |
| Balyasny Asset Management L.P. | 5,522,944 | 3.05% | $13.53M | +505,211 | 0.02% |
| Point72 Asset Management, L.P. | 4,980,526 | 2.75% | $12.20M | −984,152 | 0.01% |
| Seven Fleet Capital Management LP | 4,347,826 | 2.40% | $10.65M | +1,400,000 | 1.76% |
| Woodline Partners LP | 4,257,530 | 2.35% | $10.43M | +1,214,052 | 0.03% |
| Millennium Management LLC | 4,194,981 | 2.32% | $10.28M | −472,082 | 0.00% |
| Trails Edge Capital Partners, LP | 4,134,969 | 2.28% | $10.13M | +1,684,976 | 1.61% |
| Spruce Street Capital LP | 4,059,054 | 2.24% | $9.94M | – | 1.95% |
| Adage Capital Partners Gp, L.L.C. | 3,789,538 | 2.09% | $9.28M | – | 0.01% |
| Geode Capital Management, LLC | 2,979,529 | 1.65% | $7.30M | +1,677,865 | 0.00% |
| Two Sigma Investments, LP | 2,699,013 | 1.49% | $6.61M | +327,583 | 0.00% |
| DAFNA Capital Management LLC | 2,400,458 | 1.33% | $5.88M | −33,895 | 1.12% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 99 | 158M | 87.3% | 37 / 29 | 12 / 10 | 23M | 4M |
| Q1 2026 | 72 | 139M | 76.6% | 32 / 16 | 11 / 6 | 120M | 4M |
| Q4 2025 | 47 | 26M | 14.2% | 8 / 8 | 15 / 16 | 12M | 7M |
| Q3 2025 | 57 | 20M | 11.2% | 5 / 10 | 28 / 13 | 2M | 5M |
| Q2 2025 | 65 | 23M | 12.5% | 21 / 15 | 21 / 26 | 5M | 12M |
| Q1 2025 | 70 | 30M | 16.3% | 7 / 16 | 29 / 8 | 1M | 7M |
| Q4 2024 | 72 | 36M | 20.1% | 15 / 30 | 10 / 10 | 6M | 10M |
| Q3 2024 | 67 | 40M | 21.9% | 12 / 20 | 16 / 5 | 7M | 5M |
| Q2 2024 | 61 | 40M | 22.2% | 7 / 32 | 14 / 13 | 20M | 3M |
| Q1 2024 | 67 | 24M | 13.0% | 14 / 17 | 21 / 10 | 7M | 1M |
| Q4 2023 | 63 | 18M | 9.9% | 15 / 23 | 18 / 7 | 2M | 2M |
| Q3 2023 | 55 | 18M | 10.0% | 4 / 17 | 20 / 13 | 0M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
59 funds held IPSC in Q2 2026, 77% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IPSC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,339,806 | 2.40% | $10.63M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,900,660 | 1.60% | $7.11M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,343,126 | 0.74% | $2.71M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,222,691 | 0.68% | $3.00M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 1,106,934 | 0.61% | $2.71M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 560,308 | 0.31% | $1.37M | 0.00% | May 31, 2026 |
| Small Cap Value Fund | 549,930 | 0.30% | $1.35M | 0.20% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 413,323 | 0.23% | $1.01M | 0.07% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 299,452 | 0.17% | $604.89K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 230,383 | 0.13% | $564.44K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 200,453 | 0.11% | $491.11K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Value Index Fund | 172,406 | 0.10% | $422.39K | 0.02% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 164,276 | 0.09% | $402.48K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 163,592 | 0.09% | $330.46K | 0.01% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 131,018 | 0.07% | $320.99K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brent Pfeiffenberger | President and CEO, Director | 3,633,839 | 2.01% | Sep 15, 2026 |
| Douglas Carr | SVP Finance & Operations | 502,641 | 0.28% | Nov 5, 2026 |
| Gregory Russotti | See Remarks | 601,971 | 0.33% | Sep 15, 2026 |
| Chad Cowan | Chief Scientific Officer | 1,186,019 | 0.65% | Jun 15, 2026 |
| Adrienne Farid | Chief Operations Officer | 250,141 | 0.14% | Jun 11, 2025 |
| Morgan Conn | Chief Finanical Officer | 79,648 | 0.04% | Mar 12, 2025 |
| Joseph Truitt | Director | – | – | Sep 10, 2026 |
| Martin Patrick Murphy | Director | – | – | Jun 12, 2026 |
| Kimberly Blackwell | Director | – | – | Jun 12, 2026 |
| Alessandro Riva | Director | – | – | Jun 12, 2026 |
| Daphne Quimi | Director | 5,000 | 0.00% | Jun 12, 2026 |
| Han Myung Lee | Director | – | – | Jun 12, 2026 |
| Cynthia M. Butitta | Director | 98,936 | 0.05% | Jun 16, 2025 |
| Timothy P. Walbert | Director | – | – | Jun 16, 2025 |
| Rizzuto Carlo | Director | – | – | Jun 16, 2025 |
| Joseph Jimenez | Director | 494,346 | 0.27% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Douglas Carr SVP Finance & Operations | Nov 3, 2026 | Sale | −266 | $1.52 | $404 | 502,641 |
| Gregory Russotti See Remarks | Sep 14, 2026 | Sale | −2,587 | $1.93 | $4.99K | 509,198 |
| Douglas Carr SVP Finance & Operations | Sep 14, 2026 | Sale | −1,658 | $1.93 | $3.20K | 502,907 |
| Brent Pfeiffenberger President and CEO, Director | Sep 11, 2026 | Tax withholding | −13,850 | $1.94 | $26.87K | 3,633,839 |
| Douglas Carr SVP Finance & Operations | Sep 8, 2026 | Sale | −254 | $2.05 | $521 | 504,565 |
| Gregory Russotti See Remarks | Sep 8, 2026 | Sale | −534 | $2.05 | $1.09K | 511,785 |
| Brent Pfeiffenberger President and CEO, Director | Sep 4, 2026 | Tax withholding | −463 | $2.11 | $977 | 3,633,839 |
| Brent Pfeiffenberger President and CEO, Director | Aug 14, 2026 | Tax withholding | −31,172 | $1.92 | $59.85K | 3,634,302 |
| Douglas Carr SVP Finance & Operations | Aug 3, 2026 | Sale | −275 | $1.98 | $545 | 504,819 |
| Douglas Carr SVP Finance & Operations | Jun 12, 2026 | Sale | −1,654 | $2.23 | $3.69K | 505,094 |
| Gregory Russotti See Remarks | Jun 12, 2026 | Sale | −2,584 | $2.23 | $5.76K | 512,319 |
| Chad Cowan Chief Scientific Officer | Jun 11, 2026 | Tax withholding | −358 | $2.24 | $802 | 1,175,322 |
| Brent Pfeiffenberger President and CEO, Director | Jun 11, 2026 | Tax withholding | −13,849 | $2.24 | $31.02K | 3,665,474 |
| Douglas Carr SVP Finance & Operations | Jun 8, 2026 | Sale | −249 | $2.11 | $525 | 506,748 |
| Gregory Russotti See Remarks | Jun 8, 2026 | Sale | −524 | $2.11 | $1.11K | 514,903 |
| Brent Pfeiffenberger President and CEO, Director | Jun 5, 2026 | Tax withholding | −463 | $2.13 | $986 | 3,679,323 |
| Brent Pfeiffenberger President and CEO, Director | May 15, 2026 | Tax withholding | −31,172 | $2.34 | $72.94K | 3,679,786 |
| Douglas Carr SVP Finance & Operations | May 4, 2026 | Sale | −264 | $2.34 | $618 | 506,997 |
| Chad Cowan Chief Scientific Officer | Apr 1, 2026 | Tax withholding | −1,365 | $2.19 | $2.99K | 1,175,680 |
| Douglas Carr SVP Finance & Operations | Mar 12, 2026 | Sale | −7,043 | $2.55 | $17.96K | 507,261 |
| Gregory Russotti See Remarks | Mar 12, 2026 | Sale | −10,076 | $2.55 | $25.69K | 515,427 |
| Chad Cowan Chief Scientific Officer | Mar 11, 2026 | Tax withholding | −1,431 | $2.73 | $3.91K | 1,177,045 |
| Brent Pfeiffenberger President and CEO, Director | Mar 11, 2026 | Tax withholding | −55,397 | $2.73 | $151.23K | 3,710,958 |
| Gregory Russotti See Remarks | Mar 9, 2026 | Sale | −479 | $2.54 | $1.22K | 525,503 |
| Douglas Carr SVP Finance & Operations | Mar 9, 2026 | Sale | −247 | $2.54 | $627 | 514,304 |
| Brent Pfeiffenberger President and CEO, Director | Mar 6, 2026 | Tax withholding | −463 | $2.56 | $1.19K | 3,766,355 |
| Brent Pfeiffenberger President and CEO, Director | Feb 13, 2026 | Tax withholding | −31,172 | $1.75 | $54.55K | 3,766,818 |
| Douglas Carr SVP Finance & Operations | Feb 3, 2026 | Sale | −323 | $1.82 | $588 | 514,551 |
| Douglas Carr SVP Finance & Operations | Feb 2, 2026 | Award | +110,000 | – | – | 514,874 |
| Brent Pfeiffenberger President and CEO, Director | Feb 2, 2026 | Award | +475,000 | – | – | 3,797,990 |
| Chad Cowan Chief Scientific Officer | Feb 2, 2026 | Award | +135,000 | – | – | 1,178,476 |
| Gregory Russotti See Remarks | Feb 2, 2026 | Award | +135,000 | – | – | 525,982 |
| Chad Cowan Chief Scientific Officer | Jan 2, 2026 | Tax withholding | −1,611 | $1.00 | $1.61K | 1,043,476 |
| Chad Cowan Chief Scientific Officer | Dec 22, 2025 | Buy | +58,060 | $0.85 | $49.35K | 1,045,087 |
| Brent Pfeiffenberger President and CEO, Director | Dec 12, 2025 | Buy | +52,000 | $0.58 | $30.16K | 3,322,990 |
| Brent Pfeiffenberger President and CEO, Director | Dec 10, 2025 | Tax withholding | −463 | $0.53 | $245 | 3,270,990 |
| Douglas Carr SVP Finance & Operations | Dec 8, 2025 | Sale | −257 | $0.53 | $136 | 404,874 |
| Gregory Russotti See Remarks | Dec 8, 2025 | Sale | −526 | $0.53 | $279 | 390,982 |
| Chad Cowan Chief Scientific Officer | Nov 20, 2025 | Sale | −5,462 | $0.50 | $2.73K | 987,027 |
| Brent Pfeiffenberger President and CEO, Director | Nov 19, 2025 | Buy | +35,000 | $0.50 | $17.50K | 3,271,453 |
| Brent Pfeiffenberger President and CEO, Director | Nov 17, 2025 | Sale | −32,456 | $0.45 | $14.61K | 3,236,453 |
| Douglas Carr SVP Finance & Operations | Nov 3, 2025 | Sale | −292 | $0.59 | $172 | 405,131 |
| Chad Cowan Chief Scientific Officer | Sep 18, 2025 | Award | +762,543 | – | – | 992,489 |
| Douglas Carr SVP Finance & Operations | Sep 8, 2025 | Sale | −263 | $0.50 | $132 | 405,423 |
| Gregory Russotti See Remarks | Sep 8, 2025 | Sale | −539 | $0.50 | $270 | 391,508 |
| Brent Pfeiffenberger President and CEO, Director | Sep 8, 2025 | Sale | −488 | $0.50 | $244 | 3,268,909 |
| Brent Pfeiffenberger President and CEO, Director | Aug 14, 2025 | Award | +1,587,614 | – | – | 3,269,397 |
| Douglas Carr SVP Finance & Operations | Aug 4, 2025 | Sale | −296 | $0.53 | $157 | 405,686 |
| Adrienne Farid Chief Operations Officer | Jun 9, 2025 | Sale | −552 | $0.62 | $342 | 250,141 |
| Douglas Carr SVP Finance & Operations | Jun 9, 2025 | Sale | −4,904 | $0.62 | $3.04K | 405,982 |
| Brent Pfeiffenberger President and CEO, Director | Jun 9, 2025 | Sale | −475 | $0.62 | $295 | 1,681,783 |
| Gregory Russotti See Remarks | Jun 9, 2025 | Sale | −526 | $0.62 | $326 | 392,047 |
| Brent Pfeiffenberger President and CEO, Director | May 16, 2025 | Sale | −29,552 | $0.55 | $16.25K | 1,682,258 |
| Adrienne Farid Chief Operations Officer | May 5, 2025 | Sale | −1,024 | $0.55 | $563 | 250,693 |
| Douglas Carr SVP Finance & Operations | May 5, 2025 | Sale | −295 | $0.55 | $162 | 410,886 |
| Douglas Carr SVP Finance & Operations | Mar 11, 2025 | Award | +95,625 | – | – | 411,181 |
| Gregory Russotti See Remarks | Mar 11, 2025 | Award | +120,000 | – | – | 392,573 |
| Brent Pfeiffenberger President and CEO, Director | Mar 11, 2025 | Award | +521,500 | – | – | 1,711,810 |
| Chad Cowan Chief Scientific Officer | Mar 11, 2025 | Award | +19,500 | – | – | 230,306 |
| Adrienne Farid Chief Operations Officer | Mar 11, 2025 | Award | +120,000 | – | – | 251,717 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
18.38%
32M shares short
Days to cover
31.0
At 1M shares a day
Change since last report
+9.9%
From 29M shares
Short volume, 20 days
60.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Century Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 119,660 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Douglas Carr Officer | Nov 3, 2026 | 266 | $404 | Nov 3, 2026 | Restricted Stock Vesting |
| Gregory Russotti Officer | Sep 14, 2026 | 2,587 | $4.99K | Sep 14, 2026 | Restricted Stock Vesting |
| Douglas Carr Officer | Sep 14, 2026 | 1,658 | $3.20K | Sep 14, 2026 | Restricted Stock Vesting |
| Gregory Russotti Officer | Sep 8, 2026 | 534 | $1.09K | Sep 8, 2026 | Restricted Stock Vesting |
| Gregory Russotti Officer | Jun 12, 2026 | 2,584 | $5.77K | Jun 12, 2026 | Restricted Stock Vesting |
| Gregory Russotti Officer | Jun 8, 2026 | 524 | $1.11K | Jun 8, 2026 | Restricted Stock Vesting |
| Gregory Russotti Officer | Mar 12, 2026 | 10,076 | $25.69K | Mar 12, 2026 | Restricted Stock Vesting |
| Gregory Russotti Officer | Mar 9, 2026 | 479 | $1.21K | Mar 9, 2026 | Restricted Stock Vesting |
| Brent Pfeiffenberger Officer, Director | Dec 9, 2025 | 0 | $0 | Dec 8, 2025 | Restricted Stock Vesting |
| Brent Pfeiffenberger Officer, Director | Dec 8, 2025 | 476 | $253 | Dec 8, 2025 | Restricted Stock Vesting |
| Gregory Russotti Officer | Dec 8, 2025 | 526 | $280 | Dec 8, 2025 | Restricted Stock Vesting |
| Chad Cowan Officer | Nov 20, 2025 | 5,462 | $2.74K | Nov 20, 2025 | Restricted Stock Vesting |
| Brent Pfeiffenberger Officer, Director | Nov 17, 2025 | 32,456 | $14.73K | Nov 17, 2025 | Restricted Stock Vesting |
| Brent Pfeiffenberger Officer, Director | Sep 8, 2025 | 488 | $244 | Sep 8, 2025 | Restricted Stock Vesting |
| Gregory Russotti Officer | Sep 8, 2025 | 539 | $269 | Sep 8, 2025 | Restricted Stock Vesting |
See a number that looks wrong?